Impact BioMedical Profit Margin

The latest profit margin for IBO is 2254.29% as of June 2026. That compares with -549628.57% in the prior-year period — up 100.4% year over year. That is above the Healthcare sector average of 21.34%. Investors often review this figure alongside Impact BioMedical's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBO's profit margin moved from -549628.57% to 2254.29% — a 100.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Impact BioMedical's valuation or profitability profile.

Against Healthcare companies, IBO currently prints 2254.29% for profit margin, while the sector average sits near 21.34%. That is roughly 10466.0% above the sector mean. Large gaps often invite a closer look at Impact BioMedical's growth, margins, and balance sheet.

Profit Margin shows how effectively Impact BioMedical converts resources into returns. At 2254.29%, IBO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -549628.57% in the prior-year period — up 100.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IBO's profit margin (2254.29%), review year-over-year change from -549628.57%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.